Navigation Links
Cohera Medical Commercializes TissuGlu® Surgical Adhesive in Germany
Date:11/17/2011

PITTSBURGH, Nov. 17, 2011 /PRNewswire/ -- Cohera Medical, a rapidly growing medical device company, announced today that it has begun selling its lead product, TissuGlu® Surgical Adhesive, to hospitals and surgeons in three pilot territories in Germany.  This regional launch will document and highlight the advantages of TissuGlu and will be used to drive a wider expansion throughout Germany and to additional European markets in early 2012.

In a limited pre-launch phase started in September 2011, a select group of leading plastic and reconstructive surgeons performed over 80 plastic surgery procedures with TissuGlu.

"I am very excited for the benefits that TissuGlu will bring not only to the patients in my practice, but to plastic and reconstructive surgeons worldwide performing large-flap plastic surgery procedures," said Professor Axel-Mario Feller, an internationally renowned leader in reconstructive breast surgery based in Munich, Germany. "By reducing fluid accumulation and shortening time to drain removal, patient satisfaction and outcomes will be improved and costs of care will be reduced."

During the pre-launch, the clinical experience from using TissuGlu was shared during the OGPARC/DGPRAC/VDAPC Congress in Innsbruck, Austria, an international meeting held in late-September, attended by over 800 plastic and reconstructive surgeons. Cohera Medical also sponsored a scientific symposium that generated significant visibility and interest in the product. The resulting discussion also highlighted the potential for TissuGlu to play an important role in surgeries beyond the aesthetic field.

"The reaction to TissuGlu among the top plastic surgeons in Germany has been great.  Initial uptake by many of the most respected plastic surgeons have exceeded our initial forecast during this portion of our launch," said Patrick Daly, President and CEO of Cohera Medical. "Our focus continues to be on excellent patient outcomes and expanding the number of surgeons who utilize TissuGlu.  We look forward to continuing the rollout in additional European markets in 2012."

Currently, most patients who undergo abdominoplasty and other flap procedures require the insertion of drains to remove fluids that accumulate under the skin at the surgical site. In some cases, drainage is inadequate and the excess fluid accumulation (seroma) often requires additional procedures for removal. TissuGlu adheres the tissue flap to the underlying tissue (which is created during the procedure) to reduce fluid that can accumulate in the space and ultimately reduce the time to drain removal. With the use of TissuGlu, patients may have drains removed faster, which may lead to a more comfortable recovery and a quicker return to normal activity.

According to the American Society of Plastic Surgeons, the global market for cosmetic surgery and treatments now exceeds $30 billion, with a sustainable compound annual growth rate in the range of 25%. In Europe, the market for cosmetic surgery is about $2.2 billion with a compound annual growth rate of 19% (Frost & Sullivan), and total sales of wound closure devices are expected to reach approximately $740 million in 2012 (Medtech Insight).

About Cohera Medical

Cohera Medical, Inc.® is a rapidly growing medical device company that is actively developing a line of surgical adhesives. Cohera Medical's products are based on a unique chemical design that is resorbable, non-toxic, easy-to-use, and forms a strong bond between tissue layers. The Company's lead product, TissuGlu® Surgical Adhesive, is designed to reduce fluid accumulation and the need for surgical drains in patients undergoing abdominoplasty (tummy tuck) and other plastic procedures that require the creation of large planar flaps of tissue. Cohera Medical is also developing surgical adhesives for use as bowel sealants, for hernia mesh fixation and for small bone fixation. Outside of the EU, TissuGlu Surgical Adhesive and the other Cohera products are currently indicated for investigational use only and have not yet been approved for medical use by the Food and Drug Administration (FDA) in the U.S. or in any other market.

For more information, visit www.coheramed.com.


'/>"/>
SOURCE Cohera Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First Patient Treated in Clinical Study of Cohera Medicals TissuGlu(R) Surgical Adhesive
2. Frost & Sullivan Recognizes Cohera Medical, Inc.® for Developing TissuGlu®, Its Pioneering Surgical Adhesive That Is Strong, Easy-To-Use, Biocompatible and Resorbable
3. Cohera Medical Receives CE Mark Approval for TissuGlu® Surgical Adhesive
4. Cohera Medical and CEO Receive Pittsburgh Tech 50 Awards
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
7. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
8. Globus Medical Raises $110 Million in Series E Financing Round
9. Quark Pharmaceuticals Appoints New Chief Medical Officer
10. Boston University Biomedical Engineers Find Chink in Bacterias Armor
11. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... 26, 2016 According to a new ... Market - U.S. Industry Analysis, Size, Share, Growth, Trends, and ... the U.S. was valued at US$ 5.89 Bn in 2014 ... from 2015 to 2023 to reach US$ 7.99 Bn in ... and emerging needle free drug delivery devices and the market ...
(Date:5/26/2016)... India , May 26, 2016 ... drugs market growth is the emergence of new treatments. ... astaxanthin therapies for osteoarthritis treatment. The therapy is expected ... Moreover, Arthritis Research UK is conducting studies to develop ... arcOGEN study, where the genes involved in osteoarthritis are ...
(Date:5/26/2016)... , May 26, 2016 ... Associated With Both Cost Savings and Overall ... plc (LSE: BTG), an international specialist healthcare company, ... at the 21st Annual Meeting of ISPOR (International ... treatment of hepatocellular carcinoma (HCC) using yttrium-90 glass ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... Bunion Bootie , the manufacturer of ... was more than humbled by customer demand over the Mother’s Day Weekend promotion. So ... Now that Bunion Bootie has completely replenished its inventory levels, it hopes to continue ...
(Date:5/26/2016)... ... 2016 , ... The introduction of our professional athletes coincides with the company’s ... , “We are proud to introduce Meghan Klingenberg, defender and World Champion with ... wide receiver for Los Angeles who was a second round selection in the 2012 ...
(Date:5/26/2016)... , ... May 26, 2016 , ... May 2016 – ... so central to popular cosmetic improvement efforts. Record numbers of clients now ask about ... prominent or pouty, says Kally Papantoniou, MD, of Advanced Dermatology P.C. , ...
(Date:5/26/2016)... ... May 26, 2016 , ... Development Team of Pixel Film ... FCPX. , "This new layered style transition tool will keep a consistent flow to ... of Pixel Film Studios. , TranSweep is an all new layered style transition ...
(Date:5/26/2016)... ... 26, 2016 , ... According to the Webster’s dictionary, a hippie is defined ... products, one company is going against the norm with a line of all-natural skincare ... in the green space is proud to announce its latest retail partnership with the ...
Breaking Medicine News(10 mins):